Bayer terminates its Phase II riociguat PH-IIP trial
Bayer has announced it is terminating its Phase II study investigating riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP).
Click on this link for more information.
